SMARCB1 and synovial sarcoma: However, loss of SMARCB1 is reported in various cancers including malignant rhabdoid tumors [53,54], epithelioid sarcoma [55,56], medullary carcinoma [57,58], synovial sarcoma [59], familial schwannomatosis [60], extraskeletal myxoid chondrosarcoma [61], and small-cell hepatoblastoma [62].